Sitemap| Cellceutix at AACR |
|
Cellceutix will be presenting an abstract entitled : "Novel small molecule has potent antitumor activity in drug-resistant human carcinoma xenograft models" at a poster session on April 20. Further details are provided below: Session Title: Late-Breaking Research: Experimental and Molecular Therapeutics 2 Session Date and Time: Tuesday Apr 20, 2010 2:00 PM - 5:00 PM Location: Exhibit Hall A-C, Poster Section 39 Permanent Abstract Number: LB-283 |
Cellceutix Novel Anti-Cancer Drug Kevetrin(TM) Receives IRB and SRC Approvals for Clinical Trials at
Cellceutix Informed by FDA That 505(b)(2) Application Would Be an Acceptable Approach for Its Psoria
Cellceutix Arranges $1 Million Financing for Clinical Trials of New Cancer Drug; IND Filing Imminent
Kevetrin in Combination with Radiation Delayed Tumor Growth by Twofold in Head and Neck Cancer Study
Cellceutix Poster Presentation on its p53 Cancer Breakthrough Attracts Wide Interest at 102nd AACR M
Cellceutix Announces that it has Signed Confidential Disclosure Agreement for its Autism Drug with L
Nearing Completion of Toxicity Studies for Its Cancer Compound for Resistant Lung and Breast Cancers
Cellceutix Completes All Three Animal Safety Pharmacology Studies for Its Cancer Compound Req by FDA
Cellceutix Responds to Public Support by Expediting Autism Studies - Completes Two Required Safety P